Nippon Soda Co., Ltd. will invest ¥10 billion to build a new plant at its Nihongi Plant in Joetsu, Niigata Prefecture, to increase production of hydroxypropyl cellulose (HPC), a pharmaceutical raw material. The company plans to increase production capacity by 1.5 times to expand sales in overseas markets.
According to Nikkei reports, Nippon Soda Co., Ltd. has decided to increase production of HPC, a pharmaceutical excipient, at its Nihongi Plant in Joetsu, Niigata Prefecture. The investment will total ¥10 billion, and the company plans to strengthen its production capabilities by building a new plant.
The HPC targeted for increased production is a powdered excipient used in forming solid medicines and supplements. It is an important raw material in the processing of tablets and granules. Nippon Soda expects demand for the material to grow and aims to expand its sales channels in overseas markets.
Through this investment, the production facilities, including the new plant, are expected to increase capacity to approximately 1.5 times the current level, strengthening the company’s production and supply system. The move is intended to expand overseas sales in response to demand trends in Japan and abroad.
The article is limited to subscribers, but reports from Nikkei-affiliated media have described Nippon Soda’s increased HPC production and construction of a new plant as an initiative aimed at expanding sales channels in overseas markets. Attention is focused on future developments.